Therapeutic activation of tumor‐infiltrating lymphocytes using monoclonal antibodies targeting PD1 or PD‐L1 (immune checkpoint inhibitors—ICIs) has revolutionized treatment of specific solid tumors in adult cancer patients, and much hope has been placed on a similar effect in relapsed or refractory solid pediatric tumors. This evidence concerns the gene CD274 and neoplasm.